Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20662320 | 0.87 | NISCH (0.32) | NISCHNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL21076187 | 0.80 | LMNA (0.34) | NPC1RAB9AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL22221997 | 0.74 | CTNNB1 (0.38) | SLC5A2CTNNB1WNT3A | |
| SCHEMBL19492456 | 0.74 | CTNNB1 (0.38) | SLC5A2CTNNB1WNT3A | |
| SCHEMBL57996 | 0.72 | — | — | |
| SCHEMBL29395105 | 0.72 | — | — | |
| SCHEMBL20759067 | 0.70 | RAB9A (0.38) | NPC1RAB9AKDM4EHSD17B10 | |
| SCHEMBL18839045 | 0.68 | LTA4H (0.46) | NPC1RAB9ACTNNB1WNT3ALTA4H | |
| SCHEMBL18838084 | 0.67 | KDM4E (0.35) | SLC5A2NPC1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL19861633 | 0.67 | NISCH (0.31) | NISCHKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | SLC5A2 2629/4885NISCH 4598/4885NPC1 1516/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | SLC5A2 2265/4885NISCH 4579/4885NPC1 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.